losartan has been researched along with Carcinoma, Hepatocellular in 5 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although viral hepatocellular carcinoma (HCC) is declining, nonviral HCC, which often is the end stage of nonalcoholic or alcoholic steatohepatitis (NASH, ASH), is on an upward trajectory." | 1.91 | Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. ( Chamseddine, S; Gu, L; Huang, JY; Karin, M; Kaseb, AO; Lee, M; Mohamed, YI; Nguyen, A; Pandit, SK; Ryujin, NT; Shalapour, S; Xiao, L; Zhu, Y, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, L | 1 |
| Zhu, Y | 1 |
| Lee, M | 1 |
| Nguyen, A | 1 |
| Ryujin, NT | 1 |
| Huang, JY | 1 |
| Pandit, SK | 1 |
| Chamseddine, S | 1 |
| Xiao, L | 1 |
| Mohamed, YI | 1 |
| Kaseb, AO | 1 |
| Karin, M | 1 |
| Shalapour, S | 1 |
| Saber, S | 1 |
| Mahmoud, AAA | 1 |
| Goda, R | 1 |
| Helal, NS | 1 |
| El-Ahwany, E | 1 |
| Abdelghany, RH | 1 |
| Yoshiji, H | 2 |
| Noguchi, R | 2 |
| Namisaki, T | 2 |
| Moriya, K | 1 |
| Kitade, M | 2 |
| Aihara, Y | 2 |
| Douhara, A | 1 |
| Kawaratani, H | 2 |
| Nishimura, N | 1 |
| Fukui, H | 2 |
| Kaji, K | 1 |
| Ikenaka, Y | 1 |
| Shirai, Y | 1 |
| Yoshii, J | 1 |
| Yanase, K | 1 |
| Tsujimoto, T | 1 |
| Cook, JL | 1 |
| Zhang, Z | 1 |
| Re, RN | 1 |
5 other studies available for losartan and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells.
Topics: Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Humans; Liver Cirrhosis; Liver Neoplasms; Los | 2023 |
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineop | 2018 |
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined C | 2014 |
Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Topics: Administration, Oral; Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blocke | 2011 |
In vitro evidence for an intracellular site of angiotensin action.
Topics: Alternative Splicing; Angiotensin Receptor Antagonists; Angiotensinogen; Angiotensins; Animals; Anti | 2001 |